Skip to main content
PMC home page
Journal of Urban Health : Bulletin of the New York Academy of Medicine logoLink to Journal of Urban Health : Bulletin of the New York Academy of Medicine
. 2002 Dec 1;79(4):549–555. doi: 10.1093/jurban/79.4.549

The “ecstasy” hangover: Hyponatremia due to 3,4-Methylenedioxymethamphetamine

Stephen J Traub 1,✉, Robert S Hoffman 1, Lewis S Nelson 1
PMCID: PMC3456731  PMID: 12468674

Abstract

3,4-Methylenedioxymethamphetamine (MDMA, or “ecstasy”) has gained an undeserved reputation as a “safe” drug among its users. However, hyperthermia, rhabdomyolysis, hepatotoxicity, disseminated intravascular coagulation, long-term serotonergic neurotoxicity, and death are all associated with MDMA use. Hyponatremia is also reported, and its manifestations are frequently delayed several hours after the drug is ingested. The etiology of this hyponatremia is unclear; both the syndrome of inappropriate antidiuretic hormone release (SIADH) and free-water intoxication are advanced as explanations. We describe a 19-year-old female who presented to the emergency department with altered mental status 1 day after using MDMA. Her initial serum sodium was 121 mmol/L, and computerized tomography (CT) of her head demonstrated cerebral edema. She was treated with hypertonic saline and fluid restriction, and her serum sodium increased to 132 mmol/L over the next 24 hours. She regained consciousness completely within 48 hours of presentation and recovered uneventfully. MDMA toxicity, particularly the pathophysiology and treatment of MDMA-induced hyponatremia, are discussed.

Keywords: Public Health, Computerize Tomography, Emergency Department, Mental Status, Antidiuretic Hormone

Full Text

The Full Text of this article is available as a PDF (79.2 KB).

References

  • 1.Curran HV, Travill RA. Mood and cognitive effects of ±3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”): week-end “high” followed by mid-week low. Addiction. 1997;92:821–831. [PubMed] [Google Scholar]
  • 2.Hermle I., Spitzer M, Borchardt D, Kovar KA, Gouzoulis E. Psychological effects of MDE in normal subjects. Are entactogens a new class of psychoactive agents? Neuropsychopharmacology. 1993;8:171–176. doi: 10.1038/npp.1993.19. [DOI] [PubMed] [Google Scholar]
  • 3.Henry JA, Jeffreys KJ, Dawling S. Toxicity and deaths from 3,4-methylenedioxy-methamphetamine (“ecstasy”) Lancet. 1992;340(8816):384–387. doi: 10.1016/0140-6736(92)91469-O. [DOI] [PubMed] [Google Scholar]
  • 4.Screaton GR, Singer M, Cairns HS, Thrasher A, Sarner M, Cohen SL. Hyperpyrexia and rhabdomyolysis after MDMA (“ecstasy”) abuse. Lancet. 1992;339(8794):677–678. doi: 10.1016/0140-6736(92)90834-P. [DOI] [PubMed] [Google Scholar]
  • 5.Halachanova V, Sasone RA, McDonald S. Delayed rhabdomyolysis after ecstasy use. Mayo Clin Proc. 2001;76:112–113. doi: 10.4065/76.1.112. [DOI] [PubMed] [Google Scholar]
  • 6.Satchell SC, Connaughton M. Inappropriate antidiuretic hormone secretion and extreme rises in serum creatinine kinase following MDMA ingestion. Br J Hosp Med. 1994;51:495–495. [PubMed] [Google Scholar]
  • 7.Lehmann ED, Thom CH, Croft DN. Delayed severe rhabdomyolysis after taking “ecstasy. Postgrad Med J. 1995;71(833):186–187. doi: 10.1136/pgmj.71.833.186-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Andreu V, Mas A, Bruguera M, et al. Ecstasy: a common cause of severe a cute hepatotoxicity. J Hepatol. 1998;29:394–397. doi: 10.1016/S0168-8278(98)80056-1. [DOI] [PubMed] [Google Scholar]
  • 9.Jonas MM, Graeme-Cook FM. A 17-year-old girl with marked jaundice and weight loss. N Engl J Med. 2001;344:591–599. doi: 10.1056/NEJM200102223440808. [DOI] [PubMed] [Google Scholar]
  • 10.Parr MJ, Low HM, Botterill P. Hyponatraemia and death after “ecstasy” ingestion. Med J Aust. 1997;166(3):136–137. doi: 10.5694/j.1326-5377.1997.tb140044.x. [DOI] [PubMed] [Google Scholar]
  • 11.O'Connor A, Cluroe A, Couch R, Galler L, Lawrence J, Synek B. Death from hyponatraemia-induced cerebral oedema associated with MDMA (“ecstasy”) use. N Z Med J. 1999;112(1091):255–256. [PubMed] [Google Scholar]
  • 12.Hatzidimitriou G, McCann UD, Ricaurte GA. Altered serotonin innervation patterns in the forebrain of monkeys treated with (±) 3,4-methylenedioxymethamphetamine 7 years previously: factors influencing abnormal recovery. J Neurosci. 1999;19:5096–5107. doi: 10.1523/JNEUROSCI.19-12-05096.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.MacInnes N, Handley SL, Harding GJ. Former chronic methylenedioxymethamphetamine (MDMA or ecstasy) users report mild depressive symptoms. J Psychopharmacol. 2001;15(3):181–186. doi: 10.1177/026988110101500310. [DOI] [PubMed] [Google Scholar]
  • 14.Gouzoulis-Mayfrank E, Daumann J, Tuchtenhagen F, et al. Impaired cognitive performance in drug free users of recreational ecstasy (MDMA) J Neurol Neurosurg Psychiatry. 2000;68:719–725. doi: 10.1136/jnnp.68.6.719. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.McCann UD, Mertl M, Eligulashvili V, Ricaurte GA. Cognitive performance in (±) 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) users: a controlled study. Psychopharmacology (Berl) 1999;143:417–425. doi: 10.1007/s002130050967. [DOI] [PubMed] [Google Scholar]
  • 16.McCann UD, Szabo Z, Scheffel U, Dannals RF, Ricaurte GA. Positron emission tomographic evidence of toxic effect of MDMA (“ecstasy”) on brain serotonin neurons in human beings. Lancet. 1998;352(9138):1433–1437. doi: 10.1016/S0140-6736(98)04329-3. [DOI] [PubMed] [Google Scholar]
  • 17.Ajaelo I, Koenig K, Snoey E. Severe hyponatremia and inappropriate antidiuretic hormone secretion following ecstasy use. Acad Emerg Med. 1998;5:839–840. doi: 10.1111/j.1553-2712.1998.tb02512.x. [DOI] [PubMed] [Google Scholar]
  • 18.Gomez-Balaguer M, Pena H, Morillas C, Hernandez A. Syndrome of inappropriate antidiuretic hormone secretion and “designer drugs” (ecstasy) J Pediatr Endocrinol Metab. 2000;13:437–438. doi: 10.1515/JPEM.2000.13.4.437. [DOI] [PubMed] [Google Scholar]
  • 19.Holden R, Jackson MA. Near-fatal hyponatraemic coma due to vasopressin over-secretion after “ecstasy” (3,4-MDMA) Lancet. 1996;347(9007):1052–1052. doi: 10.1016/S0140-6736(96)90196-8. [DOI] [PubMed] [Google Scholar]
  • 20.Kessel B. Hyponatraemia after ingestion of ecstasy. BMJ. 1994;308(6925):414–414. doi: 10.1136/bmj.308.6925.414. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Maxwell DI, Polkey MI, Henry JA. Hyponatraemia and catatonic stupor after taking “ecstasy. BMJ. 1993;307(6916):1399–1399. doi: 10.1136/bmj.307.6916.1399. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Holmes SB, Banerjee AK, Alexander WD. Hyponatraemia and seizures after ecstasy use. Postgrad Med J. 1999;75(879):32–33. doi: 10.1136/pgmj.75.879.32. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Magee C, Staunton H, Tormey W, Walshe JJ. Hyponatraemia, seizures and stupor associated with ecstasy ingestion in a female. Ir Med J. 1998;91(5):178–178. [PubMed] [Google Scholar]
  • 24.Nuvials X, Masclans JR, Peracaula R, de Latorre FJ. Hyponatraemic coma after ecstasy ingestion. Intensive Care Med. 1997;23:480–480. [PubMed] [Google Scholar]
  • 25.Sharma R, Nelson LS. Methylenedioxymethylamphetamine (MDMA) induced hyponatremia. Int J Med Toxicol. 2000;3(5):29–29. [Google Scholar]
  • 26.Mas M, Farre M, dela Torre R, et al. Cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4-methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther. 1999;290:136–45. [PubMed] [Google Scholar]
  • 27.Singer GG, Brenner BM, et al. Fluid and electrolyte disturbances. In: Fauci AS, Braunwald E, Isselbacher KJ, et al., editors. Harrison's Principles of Internal Medicine. 14th ed. New York: McGraw Hill; 1998. pp. 265–277. [Google Scholar]
  • 28.Andreoli TE. Water: normal balance, hyponatremia, and hypernatremia. Renal Failure. 2000;22:711–735. doi: 10.1081/JDI-100101958. [DOI] [PubMed] [Google Scholar]
  • 29.Brownfield MS, Greathouse J, Lorens SA, Armstrong J, Urban JH, Van de Kar LD. Neuropharmacological characterization of serotoninergic stimulation of vasopressin secretion in conscious rats. Neuroendocrinology. 1988;47(4):277–283. doi: 10.1159/000124925. [DOI] [PubMed] [Google Scholar]
  • 30.Belton K, Thomas SH. Drug-induced syndrome of inappropriate antidiuretic hormone secretion. Postgrad Med J. 1999;75(886):509–510. doi: 10.1136/pgmj.75.886.509. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Kirchner V, Silver LE, Kelly CA. Selective serotonin reuptake inhibitors and hyponatraemia: review and proposed mechanisms in the elderly. J Psychopharmacol. 1998;12(4):396–400. doi: 10.1177/026988119801200411. [DOI] [PubMed] [Google Scholar]
  • 32.Henry JA, Fallon JK, Kicman AT, Hutt AJ, Cowan DA, Forsling M. Low-dose MDMA (“ecstasy”) induces vasopressin secretion. Lancet. 1998;351(9118):1784–1784. doi: 10.1016/S0140-6736(05)78744-4. [DOI] [PubMed] [Google Scholar]
  • 33.Zenenberg R, Goldfarb D. Evaluation of hyponatremia associated with use of methylenedioxy-methylamphetamine (MDMA) Int J Med Toxicol. 2000;3(5):30–30. [Google Scholar]
  • 34.Adrogue HJ, Madias NE. Hyponatremia. N Engl J Med. 2000;342:1581–1589. doi: 10.1056/NEJM200005253422107. [DOI] [PubMed] [Google Scholar]
  • 35.Wong LL, Verbalis JG. Vasopressin V2 receptor antagonists. Cardiovasc Res. 2001;51:391–402. doi: 10.1016/S0008-6363(01)00315-7. [DOI] [PubMed] [Google Scholar]
  • 36.Palm C, Reimann D, Gross P. The role of V2 vasopressin antagonists in hyponatremia. Cardiovasc Res. 2001;51:403–408. doi: 10.1016/S0008-6363(01)00288-7. [DOI] [PubMed] [Google Scholar]
  • 37.Arieff AI. Treatment of hyponatremic encephalopathy with antagonists to antidiuretic hormone. J Lab Clin Med. 2001;138:8–10. doi: 10.1067/mlc.2001.116026. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Urban Health : Bulletin of the New York Academy of Medicine are provided here courtesy of New York Academy of Medicine

RESOURCES